इसराइल - अंग्रेज़ी - Ministry of Health

sanofi israel ltd - ramipril - tablets - ramipril 2.5 mg - ace inhibitors, plain - hypertension congestive heart failure reduction of mortality in patients after mi with left ventricular dysfunction. for reducing the risk of myocardial infarction stoke cardiovascular death or need for revascularization procedures in patients over 55 years or more who have clinical evidence of cardiovascular disease (previous mi unstable angina or multivessel cabg or multivessel ptca) stroke or peripheral vascular disease. also for reducing the risk of myocardial infarction stroke cardiovascular death or need for revascularization procedures in diabetic patients of 55 years or more who have one or more of the following clinical findings : hypertension (systolic blood pressure > 160 mmhg or diastolic pressure > 90 mmhg) high total cholesterol (>5.2 mmol/l) low hdl ( <0.9 mmol/l) current smoker known microalbuminuria clinical evidence of previous vascular disease. prevention of progressive renal failure in patients with persistent proteinuria in excess of 1g/day.

इसराइल - अंग्रेज़ी - Ministry of Health

sanofi israel ltd - ramipril - tablets - ramipril 5 mg - ace inhibitors, plain - hypertension congestive heart failure reduction of mortality in patients after mi with left ventricular dysfunction. for reducing the risk of myocardial infarction stoke cardiovascular death or need for revascularization procedures in patients over 55 years or more who have clinical evidence of cardiovascular disease (previous mi unstable angina or multivessel cabg or multivessel ptca) stroke or peripheral vascular disease. also for reducing the risk of myocardial infarction stroke cardiovascular death or need for revascularization procedures in diabetic patients of 55 years or more who have one or more of the following clinical findings : hypertension (systolic blood pressure > 160 mmhg or diastolic pressure > 90 mmhg) high total cholesterol (>5.2 mmol/l) low hdl ( <0.9 mmol/l) current smoker known microalbuminuria clinical evidence of previous vascular disease. prevention of progressive renal failure in patients with persistent proteinuria in excess of 1g/day.

इसराइल - अंग्रेज़ी - Ministry of Health

sanofi israel ltd - teriflunomide - film coated tablets - teriflunomide 14 mg - teriflunomide - aubagio ® is indicated for the treatment of adult patients with relapsing remitting forms of multiple sclerosis (ms) ) to reduce the frequency of clinical relapses and to delay the progression of physical disability.

इसराइल - अंग्रेज़ी - Ministry of Health

sanofi israel ltd - valproic acid; valproic acid as sodium - tablets prolonged release - valproic acid 145 mg; valproic acid as sodium 333 mg - valproic acid - epilepsy:treatment of generalized or partial epilepsy secondary epilepsy and mixed forms of epilepsy. bipolar disorders: treatment of manic episode in bipolar disorder when lithium is contraindicated or not tolerated. the continuation of treatment after manic episode could be considered in patients who have responded to valproic acid for acute mania.

इसराइल - अंग्रेज़ी - Ministry of Health

sanofi israel ltd - insulin glargine; lixisenatide - solution for injection - lixisenatide 50 mcg / 1 ml; insulin glargine 100 units / 1 ml - insulin glargine - suliqua is indicated for the treatment of adults with insufficiently controlled type 2 diabetes mellitus to improve glycaemic control as an adjunct to diet and exercise in addition to metformin with or without sodium-glucose co-transporter-2 (sglt-2) inhibitors.

इसराइल - अंग्रेज़ी - Ministry of Health

sanofi israel ltd - cemiplimab - concentrate for solution for infusion - cemiplimab 50 mg / 1 ml - cemiplimab - cutaneous squamous cell carcinoma libtayo as monotherapy is indicated for the treatment of adult patients with metastatic or locally advanced cutaneous squamous cell carcinoma who are not candidates for curative surgery or curative radiation.basal cell carcinoma libtayo as monotherapy is indicated for the treatment of adult patients with locally advanced or metastatic basal cell carcinoma (labcc or mbcc) who have progressed on or are intolerant to a hedgehog pathway inhibitor (hhi).

इसराइल - अंग्रेज़ी - Ministry of Health

sanofi israel ltd - diphtheria toxoid; filamentous haemagglutinin (fha); fimbrae tupes 2 + 3 (fim); inactivated polio virus (ipv) type 1; inactivated polio virus (ipv) type 2; inactivated polio virus (ipv) type 3; pertactin (prn); pertussis toxoid vaccine; tetanus toxoid - suspension for injection - fimbrae tupes 2 + 3 (fim) 5 mcg/dose; pertussis toxoid vaccine 2.5 mcg/dose; filamentous haemagglutinin (fha) 5 mcg/dose; pertactin (prn) 3 mcg/dose; diphtheria toxoid 2 lf / 1 doses; tetanus toxoid 5 lf / 1 doses; inactivated polio virus (ipv) type 1 40 du/dose; inactivated polio virus (ipv) type 2 8 du/dose; inactivated polio virus (ipv) type 3 32 du/dose - diphtheria-pertussis-poliomyelitis-tetanus - diphtheria-pertussis-poliomyelitis-tetanus - active immunization against diphtheria, tetanus, pertussis and poliomyelitis in subjects aged 4 years and over as a booster following primary immunisation.adacel polio is not indicated for primary immunisation. adacel polio is not indicated for treating diseases caused by b.pertussis, c.diphtheriae or c.tetani or by poliomyelitis infections

इसराइल - अंग्रेज़ी - Ministry of Health

sanofi israel ltd - tuberculin purified protein - solution for injection - tuberculin purified protein 5 tu / 0.1 ml - tuberculosis diagnostics - an aid in the detection of infection with mycobacterium tuberculosis.

इसराइल - अंग्रेज़ी - Ministry of Health

sanofi israel ltd - yellow fever virus strain 17d204 (substrain ab237) - powder and solvent for suspension for injection - yellow fever virus strain 17d204 (substrain ab237) - yellow fever, live attenuated - stamaril is indicated for active immunization against yellow fever in persons:• travelling to, passing through or living in an endemic area,• travelling to any country that requires an international certificate of vaccination for entry(which may or may not depend on the previous itinerary).• handling potentially infectious materials (e.g. laboratory personnel).see sections 4.2, 4.3 and 4.4 regarding the minimum age for vaccination of children under special circumstances and guidance for vaccination of other specific patient populations.in order to comply with vaccine regulations and to be officially recognized, yellow fever vaccines must be administered in an approved world health organization (who) vaccination centre and registered on an international certificate of vaccination. the validity period of thiscertificate is established according to international health regulations (ihr) recommendations, and starts 10 days after primary vaccination and immediately after re-vaccination (see section 4.2).

इसराइल - अंग्रेज़ी - Ministry of Health

sanofi - aventis israel ltd - adenosine - solution for injection - adenosine 6 mg / 2 ml - adenosine - adenosine - rapid conversion to a normal sinus rhythm of paroxysmal supraventicular tachycardias including those associated with accessory bypass tracts (wolf parkinson-white syndrome).